Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...
The global amniotic products market is projected to grow at a CAGR of approximately 8%, reaching nearly USD 1 billion by 2031 ...
The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive alternative to glasses or surgery. Phase 3 trials demonstrated superior ...
The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results